Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. (Q51122702)

30 March 2018

meta-analysis

0 references

title

Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. (English)

1 reference

30 March 2018

0 references

Agata Ptaszynska

1

1 reference

30 March 2018

Kristina M Johnsson

2

1 reference

30 March 2018

Shamik J Parikh

3

1 reference

30 March 2018

Tjerk W A de Bruin

4

1 reference

30 March 2018

Anne Marie Apanovitch

5

1 reference

30 March 2018

James F List

6

1 reference

30 March 2018

publication date

1 October 2014

1 reference

30 March 2018

published in

Drug Safety

1 reference

30 March 2018

volume

37

1 reference

30 March 2018

issue

10

1 reference

30 March 2018

page(s)

815-829

1 reference

30 March 2018

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Renal homeostasis and tubuloglomerular feedback

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0213-4

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25096959

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25096959

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40264-014-0213-4

1 reference

30 March 2018

release_ph7xv7ihqvd2dczu5dm2oqcijy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ph7xv7ihqvd2dczu5dm2oqcijy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

30 March 2018